GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sigyn Therapeutics Inc (OTCPK:SIGY) » Definitions » Net Interest Income

SIGY (Sigyn Therapeutics) Net Interest Income : $-1.34 Mil (TTM As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Sigyn Therapeutics Net Interest Income?

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. Sigyn Therapeutics's net interest income for the three months ended in Sep. 2024 was $-0.36 Mil. Its net interest income for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.34 Mil.


Sigyn Therapeutics Net Interest Income Historical Data

The historical data trend for Sigyn Therapeutics's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sigyn Therapeutics Net Interest Income Chart

Sigyn Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.06 -0.34 -0.46 -0.78 -2.04

Sigyn Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.27 -0.59 -0.13 -0.26 -0.36

Sigyn Therapeutics Net Interest Income Calculation

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors.

Net Interest Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sigyn Therapeutics Net Interest Income Related Terms

Thank you for viewing the detailed overview of Sigyn Therapeutics's Net Interest Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Sigyn Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
2468 Historic Decatur Road, Suite 140, San Diego, CA, USA, 92106
Sigyn Therapeutics Inc is a development-stage therapeutic technology company. Its business focus is the clinical advancement of Sigyn Therapy, a multi-function blood purification technology designed to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the cause of hospital deaths world-wide. To support widespread implementation, the company designed Sigyn Therapy to be a single-use disposable device that is deployable on the world-wide infrastructure of hemodialysis and continuous renal replacement therapy machines already located in hospitals and clinics.
Executives
Joseph Segelman director, 10 percent owner, officer: President & CEO 9190 W OLYMPIC BLVD, # 263, BEVERLY HILLS CA 90212
Australian Sapphire Corp 10 percent owner 9190 W OLYMPIC BLVD, BEVERLY HILLS CA 90212
Chaya Segelman director, officer: Secretary 9190 W OLYMPIC BLVD, # 263, BEVERLY HILLS CA 90212